In vitro activity of eravacycline in combination with colistin against carbapenem-resistant A. baumannii isolates

[1]  Rui Wang,et al.  Safety and efficacy of colistin alone or in combination in adults with Acinetobacter baumannii infection: A systematic review and meta-analysis. , 2019, International journal of antimicrobial agents.

[2]  Ronald N. Jones,et al.  Antimicrobial Susceptibility of Acinetobacter calcoaceticus–Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997–2016) , 2019, Open forum infectious diseases.

[3]  S. Lewycka,et al.  A Systematic Review and Meta-analysis of Ventilator-associated Pneumonia in Adults in Asia: An Analysis of National Income Level on Incidence and Etiology , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  Clinical,et al.  Performance standards for antimicrobial susceptibility testing , 2019 .

[5]  J. Solomkin,et al.  IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  R. Bonomo,et al.  New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections , 2018, Antimicrobial Agents and Chemotherapy.

[7]  L. Leibovici,et al.  Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. , 2018, The Lancet. Infectious diseases.

[8]  J. Karlowsky,et al.  In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015. , 2017, Diagnostic microbiology and infectious disease.

[9]  Ö. Ergönül,et al.  Rapid emergence of colistin resistance and its impact on fatality among healthcare-associated infections. , 2017, The Journal of hospital infection.

[10]  M. Falagas,et al.  Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis. , 2017, International journal of antimicrobial agents.

[11]  C. Sheu,et al.  Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  E. Pérez-Nadales,et al.  The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[13]  P. Higgins,et al.  In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. , 2018, International journal of antimicrobial agents.

[14]  J. Vila,et al.  High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial , 2017, The Journal of antimicrobial chemotherapy.

[15]  S. Pournaras,et al.  Evaluation of two automated systems for colistin susceptibility testing of carbapenem‐resistant Acinetobacter baumannii clinical isolates , 2017, The Journal of antimicrobial chemotherapy.

[16]  N. M. Mutlu,et al.  Analysis of epidemiology and risk factors for mortality in ventilator-associated pneumonia attacks in intensive care unit patients. , 2017, Turkish journal of medical sciences.

[17]  A. Tsakris,et al.  Predominance of international clone 2 OXA-23-producing-Acinetobacter baumannii clinical isolates in Greece, 2015: results of a nationwide study. , 2017, International journal of antimicrobial agents.

[18]  M. Mohammadi,et al.  Synergistic Effect of Colistin and Rifampin Against Multidrug Resistant Acinetobacter baumannii: A Systematic Review and Meta-Analysis , 2017, The open microbiology journal.

[19]  J. Solomkin,et al.  Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial , 2016, JAMA surgery.

[20]  Ş. Direkel,et al.  [Investigation of the frequency and distribution of beta-lactamase genes in the clinical isolates of Acinetobacter baumannii collected from different regions of Turkey: a multicenter study]. , 2016, Mikrobiyoloji bulteni.

[21]  Y. Hamada,et al.  Antibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms , 2016, Antimicrobial Agents and Chemotherapy.

[22]  N. Woodford,et al.  In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii , 2016, Antimicrobial Agents and Chemotherapy.

[23]  J. Karlowsky,et al.  Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent , 2016, Drugs.

[24]  C. Hou,et al.  Drug-resistant gene of blaOXA-23, blaOXA-24, blaOXA-51 and blaOXA-58 in Acinetobacter baumannii. , 2015, International journal of clinical and experimental medicine.

[25]  B. Gu,et al.  Increasing resistance rate to carbapenem among blood culture isolates of Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa in a university-affiliated hospital in China, 2004–2011 , 2014, The Journal of Antibiotics.

[26]  You-ning Liu,et al.  International Journal of Antimicrobial Agents , 2014 .

[27]  Central Asian and Eastern European Surveillance of Antimicrobial Resistance , 2015 .

[28]  D. Landman,et al.  Activity of Eravacycline against Enterobacteriaceae and Acinetobacter baumannii, Including Multidrug-Resistant Isolates, from New York City , 2014, Antimicrobial Agents and Chemotherapy.

[29]  T. Grossman,et al.  Antibacterial Activity of Eravacycline (TP-434), a Novel Fluorocycline, against Hospital and Community Pathogens , 2013, Antimicrobial Agents and Chemotherapy.

[30]  Daniel N. Wilson,et al.  Target- and Resistance-Based Mechanistic Studies with TP-434, a Novel Fluorocycline Antibiotic , 2012, Antimicrobial Agents and Chemotherapy.

[31]  P. Nordmann,et al.  Genetic Features of the Widespread Plasmid Coding for the Carbapenemase OXA-48 , 2011, Antimicrobial Agents and Chemotherapy.

[32]  N. Woodford,et al.  Phylogenetic diversity of Escherichia coli strains producing NDM-type carbapenemases. , 2011, The Journal of antimicrobial chemotherapy.

[33]  J. Mingorance,et al.  Detection of KPC-2-producing Citrobacter freundii isolates in Spain. , 2010, The Journal of antimicrobial chemotherapy.

[34]  R. Jones,et al.  Metallo-β-Lactamase Gene blaIMP-15 in a Class 1 Integron, In95, from Pseudomonas aeruginosa Clinical Isolates from a Hospital in Mexico , 2008, Antimicrobial Agents and Chemotherapy.

[35]  Shu-sen Zheng,et al.  Dissemination of imipenem-resistant Acinetobacter baumannii strains carrying the ISAba1 blaOXA-23 genes in a Chinese hospital. , 2007, Journal of medical microbiology.

[36]  T. Gootz,et al.  High-Level Carbapenem Resistance in a Klebsiella pneumoniae Clinical Isolate Is Due to the Combination of blaACT-1 β-Lactamase Production, Porin OmpK35/36 Insertional Inactivation, and Down-Regulation of the Phosphate Transport Porin PhoE , 2006, Antimicrobial Agents and Chemotherapy.

[37]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[38]  K J Ryan,et al.  Antimicrobial Susceptibility Testing , 2016, Advances in Experimental Medicine and Biology.